Articles

Developing novel targeted therapies for patients with cancer who have rare mutations, such as PI3K/AKT/mTOR pathway alterations, is particularly challenging for researchers. Read More ›

Patients with platinum-pretreated small-cell lung cancer may benefit from combination use of cediranib, an oral VEGF inhibitor, and olaparib, a PARP inhibitor. Read More ›

Despite the approval of immune checkpoint inhibitors for patients with lung cancers, their role in rare pulmonary tumors, such as large-cell neuroendocrine carcinoma of the lung, has remained unclear. Read More ›

Immune-related adverse events did not affect the clinical benefit of consolidation checkpoint inhibitor therapy after chemoradiation in stage III non–small-cell lung cancer. Read More ›

After 3 years of follow-up, nivolumab combined with ipilimumab demonstrates sustained overall survival rates in treatment-naïve patients with advanced non–small-cell lung cancer. Read More ›

The addition of 2 cycles of chemotherapy to the combination of nivolumab and ipilimumab results in superior overall survival in treatment-naïve patients with advanced non–small-cell lung cancer. Read More ›

Stereotactic ablative radiotherapy combined with immunotherapy (I-SABR) is well-tolerated in patients with early-stage, medically inoperable, isolated-recurrence non–small-cell lung cancer without lymph node or distant metastasis. Read More ›

Based on a meta-analysis of randomized trials in the first-line treatment of non–small-cell lung cancer, adding chemotherapy to immune checkpoint inhibitors (ICIs) improves response rates and progression-free survival in some patients compared with ICI monotherapy, but does not confer an overall survival benefit regardless of PD-L1 status. Read More ›

Standard treatment for patients with advanced malignant pleural mesothelioma is predominantly chemotherapy-based. Nivolumab may be effective in these patients based on a retrospective real-world data assessment. Read More ›

The combinations of nivolumab with gemcitabine/cisplatin or nivolumab with ipilimumab were tested in patients with untreated advanced biliary tract cancer. Read More ›